GLP 1 pharmacy support needs a payment route says Milken Institute report
A Milken Institute report backed by the chain pharmacy trade group says pharmacists can help keep GLP 1 users on treatment, and asks payers and lawmakers to pay for counseling and coverage work that pharmacies now do for free.
Who feels it
-
Pharmacies
Rethink
Proposes billing routes for GLP 1 counseling and navigation work that is mostly unpaid today.
-
Payers
Adjust
Asked to build pharmacy support into coverage and use dispensing data to track adherence.
-
Patients
Worth knowing
Pharmacists may offer more help with side effects and coverage, but no new paid service or date exists yet.
-
Prescribers
Worth knowing
The report asks you to settle coverage before the pharmacy and share dose plans with pharmacists.
-
Sellers
Passes by
—
A Milken Institute report released on November 11 argues that GLP 1 pharmacy support should become a paid service rather than unpaid help at the counter. It says community pharmacists can keep patients on treatment through side effects, refills and coverage hurdles, but only if payers and lawmakers create a way to pay for that work. The report was backed by the National Association of Chain Drug Stores, whose own survey found that most GLP 1 users trust pharmacists and would like more time with them.
What the Milken Institute report found
The report, titled Beyond the Prescription: Community Pharmacy's Role in Comprehensive GLP-1 Care, was launched at the Milken Institute Future of Health Summit in Washington. Its four authors, led by institute director Athena Rae Roesler, drew on interviews with pharmacies, patient groups, payers and drug makers, plus opinion research. They treat obesity and related heart and metabolic disease as chronic conditions that need care well after the first fill: help with dose steps, side effects, staying on the drug, diet and exercise, and links between prescribers and plans. The paper groups its findings under four themes, from the pharmacy as an easy place to reach to the gaps in systems and staffing that stop pharmacies from offering the same care everywhere.
Access friction gets its own theme, and it is the part closest to cost. Drug Topics, summing up the report, says complex prior authorization rules and surprise out of pocket bills often leave prescriptions unclaimed at the pharmacy. Pharmacy staff often step in as navigators, looking for drugs on the plan list, sending prior authorization requests and routing claims to savings programs. The report points to the Medicare GLP 1 Bridge, which cut copays for some beneficiaries, as an example of a fast change in access that few patients know about. Drug Topics also cited figures in the report showing that between 47 and 68 percent of people stop their GLP 1 drug within the first year, and more than 70 percent by year two.
The survey behind the GLP 1 pharmacy support push
The chain pharmacy group paid for a national poll by Public Opinion Strategies of 1,200 adults, including current, former and likely GLP 1 users. In that poll, 74 percent of users said more chances to work with a pharmacist would improve their experience and results. Confidence in pharmacists for GLP 1 questions reached 93 percent among users and 83 percent among all adults, close to the 97 percent users gave physicians and well above the 70 percent they gave telehealth services. Users also said they would value resources on physical activity, starter kits with educational material and referrals to dietitians. The poll was released by a trade group that represents chain pharmacies, so its framing serves members who want to be paid for this work.
In that poll, 74 percent of users said more chances to work with a pharmacist would improve their experience and results.
Steven Anderson, the group's chief executive, put the case in one line. "A prescription is a beginning, not a finish line," he said in the release. The survey numbers in the table below come from that release and cover six of its findings. They measure opinions, not outcomes: the report does not show that more pharmacist time keeps people on treatment longer or lowers costs. That evidence gap matters for payers, who have heard similar pitches from coaching firms and employer companion programs in recent weeks. A pharmacy service that can show fewer people stopping in the first year would make a stronger case than any poll.
| Survey finding | Share |
|---|---|
| GLP 1 users who say more pharmacist time would help | 74% |
| GLP 1 users confident in pharmacists for GLP 1 questions | 93% |
| All adults confident in pharmacists for GLP 1 questions | 83% |
| GLP 1 users confident in physicians | 97% |
| GLP 1 users confident in telehealth | 70% |
| GLP 1 users who value starter kits | 89% |
Why dispensing alone does not pay pharmacies
The money problem sits underneath the whole report. Nicole Pezzino, a pharmacist quoted by Drug Topics, says dispensing GLP 1 drugs alone is rarely profitable, which leaves little room to fund counseling for free. That strain limits how much unpaid clinical care a pharmacy can give, so check in calls, side effect advice and prior authorization work compete with dispensing for staff time. Pezzino has proposed a framework for pharmacy teams that covers finding patients, first counseling, regular refill check ins and tracking measures such as weight and blood sugar. She argues those records can turn daily help into evidence that prescribers and plans will accept as a basis for paying for the service.
The report's answer is a set of payment routes. It asks policymakers to create reimbursement for pharmacist GLP 1 care, including counseling, medication management and nutrition referrals, and to weigh bills that would widen Medicare and Medicaid coverage of the drugs for obesity. Drug Topics adds that leaders back formal billing codes, collaborative practice agreements with prescribers and expanded medication therapy management. Some chains already offer a version of this, as in the Walgreens pharmacist calls program we covered last month. None of these GLP 1 pharmacy support steps has a date, a price or a named sponsor in the report, so they remain proposals for now rather than changes a patient will see.
What payers and prescribers are asked to do
For health plans, the report asks for pharmacy support to be built into any expansion of GLP 1 coverage and for pharmacy dispensing data to be used to track whether people keep taking their drug. It also suggests using the temporary Medicare GLP 1 Bridge demonstration to gather evidence on what works. Prescribers are asked to settle coverage questions before a patient reaches the pharmacy, and to share protocols and close the loop with pharmacists on dose changes and side effects. Those steps aim at the same failure point: a patient who arrives at the counter, meets a rejection or a large copay and walks away without the medicine.
Patients get one concrete request. The report asks people who get a GLP 1 drug through telehealth or an online platform to tell a local pharmacist, so someone can check for interactions and side effects. That matters because many users now get the drugs outside regular insurance and pharmacies, and those records are often invisible to local care teams. A pharmacist who does not know about a drug bought through an app cannot warn about stomach side effects, missed doses or a clash with other medicines. The full report sits on the Milken Institute site, and the survey details come from the chain pharmacy group release and the Drug Topics summary issued the same week.
Conclusion
The Milken report makes GLP 1 pharmacy support a payment question more than a clinical one. Pharmacists already do much of the coverage and side effect work, and the chain pharmacy group that backed the report wants payers and governments to pay for it. Whether that happens depends on billing rules and plan contracts that do not exist yet, and on proof that the service keeps people on treatment. This is reporting on a policy report, not medical advice.
Source Milken Institute report Beyond the Prescription (November 11, 2026); NACDS release with Public Opinion Strategies survey of 1,200 adults; Drug Topics summary
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.